Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 674-684

  Billioud, Vincent ^a   Sandborn, William J ^b   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID;

CLINICAL EVALUATION; COLON DISEASE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; ENTERITIS; FAMILY HISTORY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION RETRIEVAL; MAINTENANCE THERAPY; MEDLINE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSMOLAR CONCENTRATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79953786419     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.60     Document Type: Review

References (51)

1. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
2. Sandborn WJ, Rutgeerts P, Enns R et al Adalimumab induction therapy for Crohn disease previously treated with Infiximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
3. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
4. Colombel JF, Sandborn WJ, Rutgeerts P et al Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009; 104: 1170-9.
5. Clark M, Colombel JF, Feagan BC et al American gastroenterological association consensus development conference on the use of biologics in the treatment of Infammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39. (Pubitemid 47031141)
6. Dignass A, Van Assche G, Lindsay JO et al Te second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
7. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effcacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6: 644-53. (Pubitemid 351783447)
8. Cassinotti A, Travis S. Incidence and clinical signif cance of immunogenic-ity to Infiximab in Crohn's disease: a critical systematic review. Infamm Bowel Dis 2009;15:1264-75.
9. Gisbert JP Panes J. Loss of response and requirement of Infiximab dose intensif cation in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
10. Papadakis KA, Shaye OA, Vasiliauskas EA et al Safety and Effcacy of adali-mumab (D2E7) in Crohn's disease patients with an attenuated response to infiximab. Am J Gastroenterol 2005;100:75-9. (Pubitemid 41623272)
11. Mackowiak J, Sederman R. P089 Adalimumab induction and maintenance: analysis of prescribed vs recommended doses among patients with Crohn's disease in the United States. J Crohns Colitis Suppl 2008;2:32.
12. Sandborn WJ, Hanauer SB, Rutgeerts P et al Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9. (Pubitemid 47300424)
13. Sandborn WJ, Colombel JF, Lomax KG et al Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: data from EXTEND. Am J Gastroenterol 2010;105:S442.
14. Sandborn WJ, Colombel JF, Schreiber S et al Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical Effcacy and pharmacoeconomics. Infamm Bowel Dis 2011;17:141-51.
15. Panaccione R, Colombel JF, Sandborn WJ et al Adalimumab sustains clinical remission and overall clinical benef t af er 2 years of therapy for Crohn's disease. Aliment Pharmacol Ter 2010;31:1296-309.
16. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to Infiximab: an open-label study Aliment Pharmacol Ter 2007;25: 675-80.
17. Ng SC, Plamondon S, Gupta A et al Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fstulas. Am J Gastroenterol 2009;104:2973-86.
18. Karmiris K, Paintaud G, Noman M et al Inffuence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
19. Rizzello F, Gionchetti P, Brugnera R et al. Adalimumab is effective in the treatment of active luminal Crohn's disease and mucosal healing: a single center experience in 170 patients. Gut 2009;58 (Suppl 2): A171.
20. Rizzello F, Gionchetti P, Tambasco R et al Adalimumab in the treatment of active luminal and perianal Crohn's disease: a single center experience in 100 patients. Gastroenterology 2009; 136: A-177.
21. Bultman E, West RL, van Liere-Baron A et al. Previous non-response to Infiximab predicts early dose-escalation in adalimumab treated Crohn's disease patients. Gastroenterology 2010;138:S-701-2.
22. Gionchetti P, Rizzello F Tambasco R et al Adalimumab in the treatment of perianal Crohn's disease: a single center in 64 patients. Gastroenterology 2010;138:S-328.
23. Viola F, Civitelli F Di Nardo G et al. Effcacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009; 104: 2566-71.
24. Ho GT, Smith L, Aitken S et al. Te use of adalimumab in the manage-ment of refractory Crohn's disease. Aliment Pharmacol Ter 2008;27: 308-15.
25. West RL, Zelinkova Z, Wolbink GJ et al Immunogenicity negatively Inffuences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ter 2008;28:1122-6.
26. Lopez Palacios N, Mendoza JL, Taxonera C et al. Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study Rev Esp EnfermDig 2008;100:676-81.
27. Sheridan JA, Keegan D, Slattery E et al Adalimumab in Crohn's disease. Gut 2008;57 (Suppl 2): A2564.
28. Oussalah A, Babouri A, Chevaux JB et al Adalimumab for Crohn's disease with intolerance or lost response to Infiximab: a 3-year single-centre expe-rience. Aliment Pharmacol Ter 2009;29:416-23.
29. Lees CW, Ali AI, Tompson AI et al. Te safety prof le of anti-tumour necrosis factor therapy in Infammatory bowel disease in clinical prac-tice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ter 2009; 29: 286-97.
30. Kemp K, Dibb M, Makin AJ et al. 2 year follow up of adalimumab therapy in patients with Crohn's disease. J Crohns Colitis 2009; 3: S27-8.
31. Bortlik M, Duricova D, Komarek V et al Adalimumab in a clinical prac-tice\experience with human anti TNF-[alpha] therapy in tertiary clinical center. Gastroenterology 2009;136:A-682.
32. Cohen RD, Lewis JR, Turner H et al Predictors and timing of adalimumab (ADA) dose escalation in patients with Crohn's disease (CD). Gastroenterology 2009;136:A-652.
33. Naik AS, Qumseya B, Ananthakrishnan AN et al. Anti-TNF therapy for Crohn's disease: predictors of dose escalation and early discontinuation by 1 yearoftherapy Gastroenterology 2009;136:A-654.
34. Swoger JM, Lofus EV Jr, Tremaine WJ et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the frst 118 patients. Infamm Bowel Dis 2010;16:1912-21.
35. Wolf DC, Wolf CH. Persistencyequals Effcacy in adalimumab patients: preliminary report of a large single site experience. Gastroenterology 2010;138:S-699.
36. Chaparro M, Panes J, García V et al Long-term durability of response to adalimumab treatment in Crohn's disease. Gastroenterology 2010; 138:S-689.
37. Shafran I, Cangemi D, Burgunder P. Effcacy of adalimumab therapy in patients with Crohn's disease who were unresponsive to or intolerant of Infiximab: six years of experience in a single gastroenterology center. Am J Gastroenterol 2010;105:S444.
38. Wyneski MJ, Green A, Kay M et al Safety and Effcacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008;47:19-25.
39. Rosenbach Y, Hartman C, Shapiro R et al. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010;55: 747-53.
40. Ho GT, Mowat A, Potts L et al Effcacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ter 2009;29: 527-34.
41. Allez M, Vermeire S, Mozziconacci N et al Te Effcacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease af er failure of two other anti-TNF antibodies. Aliment Pharmacol Ter 2010;31: 92-101.
42. Nichita C, Stelle M, Vavricka et al Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion 2010;81:78-85.
43. Russo EA, Iacucci M, Lindsay JO et al Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010;22:334-9.
44. Russo E, O ' Donnell S, Dearden J et al Long term Effcacy of the second biologic in the management of Crohn's disease. A retrospective survey on an English-Irish cohort. Gastroenterology 2010; 138: S-697.
45. Ormaechea JIF, Gonzalez-Lama Y, Casis B et al Adalimumab for luminal and perianal Crohn's disease in real practice: a long-term multicenter study of effectiveness, safety and predictors of response. Gastroenterology 2010;138:S-697.
46. Rosh JR, Lerer T, Markowitz J et al Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9.
47. Lofus EV, Pan X, Zurawski P et al Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohn's disease in the US. Gastroenterology 2009;136:A-175.
48. Plevy S, Lu M, Yu A et al Observational study of treatment patterns in patients newly initiated with adalimumab or Infiximab therapy for Crohn's disease. Am J Gastroenterol 2009; 104: S479.
49. Rubin D, Reinisch W, Bensimon A et al Predictors ofclinical response and maintenance of response in Crohn's disease: data from CHARM. Am J Gastroenterol 2009;104:S478.
50. Van Assche G, Vermeire S, Rutgeerts P. Te potential for disease modif cation in Crohn's disease. Nat Rev Gastroenterol Hepatol 2010; 7: 79-85.
51. Tromberg-Camps MJ, DagneliePC, KesterAD et al. Inffuence of pheno-type at diagnosis and of other potential prognostic factors on the course of infammatorybowel disease. Am J Gastroenterol 2009;104:371-83.